Biosketch

Toni K. Choueiri, MD is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at DFCI and past President of the Medical Staff at DFCI. He has received multiple national and international awards including the Giants of Cancer Care Award and the King Hussein Cancer Research Award, is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania and currently serves as an American Society of Clinical Oncology (ASCO) Board member (2024-2028).

Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). Dr. Choueiri led clinical trials that resulted in the approval of several novel cancer therapies which have defined the treatment of RCC. His laboratory work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.

Dr. Choueiri has received research funding from the U.S. National Cancer Institute, the U.S. Department of Defense (DOD), and industry partners. His work has been published in prestigious journals such as the New England Journal of Medicine, The Lancet, Science, Nature, and Nature Medicine. He has over 850 PubMed-indexed publications, and an H-index of 150 (Google scholar, June 1 2025).